La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Canada7508
Philippe Huot26
Canada Sauf Philippe Huot" 7484
Philippe Huot Sauf Canada" 2
Canada Et Philippe Huot 24
Canada Ou Philippe Huot 7510
Corpus8669
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 24.
Ident.Authors (with country if any)Title
000060 Karim Selfani [Canada] ; Valérie L. Soland ; Sylvain Chouinard ; Philippe HuotMovement Disorders Induced by the "Atypical" Antipsychotic Aripiprazole.
000536 Philippe Huot [Canada] ; William D. Hutchison [Canada]Serotonin/dopamine transporter ratio as a predictor of L-dopa-induced dyskinesia.
000641 Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada]Monoamine Reuptake Inhibitors in Parkinson's Disease
000877 Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Katie D. Lewis [Australie] ; James B. Koprich [Canada] ; M Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada]UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
000C38 Philippe Huot [Canada] ; Susan H. FoxThe serotonergic system in motor and non-motor manifestations of Parkinson's disease.
000C43 Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Susan H. Fox ; Jonathan M. BrotchieThe pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
000C50 James B. Koprich [Canada] ; Philippe Huot ; Susan H. Fox ; Keith Jarvie ; Anthony E. Lang ; Philip Seeman ; Jonathan M. BrotchieThe effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.
000F09 Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tessa Snoeren [Pays-Bas] ; James B. Koprich [Canada] ; Michael P. Hill [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada]Use of catechol‐O‐methyltransferase inhibition to minimize L‐3,4‐dihydroxyphenylalanine‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned macaque
001036 Philippe Huot [Canada] ; Susan H. Fox [Canada]The serotonergic system in motor and non-motor manifestations of Parkinson's disease
001038 James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada]The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques
001116 Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Michael N. Gandy [Australie] ; M. Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada]The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset
001191 Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Ahmed Aman ; Susan H. Fox ; Jonathan M. BrotchieL-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
001293 Tom H. Johnston [Canada] ; Zak Millar ; Philippe Huot ; Keith Wagg ; Sherri Thiele ; Danielle Salomonczyk ; Christopher J. Yong-Kee ; Michael N. Gandy ; Matthew Mcildowie ; Katie D. Lewis ; Jordi Gomez-Ramirez ; Joohyung Lee ; Susan H. Fox ; Mathew Martin-Iverson ; Joanne E. Nash ; Matthew J. Piggott ; Jonathan M. BrotchieA novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.
001413 Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Tayyeba Darr [Canada] ; Donna Pires [Canada] ; Lili-Naz Hazrati [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease
001574 Philippe Huot [Canada] ; Susan H. Fox ; Jonathan M. BrotchieThe serotonergic system in Parkinson's disease.
001723 Philippe Huot [Canada] ; Susan H. Fox ; Adrian Newman-Tancredi ; Jonathan M. BrotchieAnatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?
001743 Philippe Huot [Canada] ; Jonathan M. Brotchie5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms.
001B24 Michael N. Gandy [Australie] ; Matthew Mcildowie [Australie] ; Katie Lewis [Australie] ; Agata M. Wasik [Royaume-Uni] ; Danielle Salomonczyk [Canada] ; Keith Wagg [Australie] ; Zak A. Millar [Australie] ; David Tindiglia [Australie] ; Philippe Huot [Canada] ; Tom Johnston [Canada] ; Sherri Thiele [Canada] ; Blake Nguyen [Australie] ; Nicholas M. Barnes [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Mathew T. Martin-Iverson [Australie] ; Joanne Nash [Canada] ; John Gordon [Royaume-Uni] ; Matthew J. Piggott [Australie]Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity
001C09 Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations
001C89 Susan H. Fox [Canada] ; Naomi Visanji [Canada] ; Gaby Reyes [Canada] ; Philippe Huot [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom Johnston [Canada] ; Jonathan M. Brotchie [Canada]Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson's Disease
001D05 Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Increased 5-HT2A Receptors in the Temporal Cortex of Parkinsonian Patients with Visual Hallucinations
002428 Philippe Huot [Canada] ; Martin Lévesque ; André ParentThe fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
002632 Philippe Huot [Canada] ; Martin Levesque [Canada] ; André Parent [Canada]The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea
002683 Philippe Huot [Canada] ; André Parent [Canada]Dopaminergic neurons intrinsic to the striatum

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022